We offer a number of tests to help clinicians understand which approved anti-cancer treatments should be most effective for their patients.
Our tests can also direct patients to off-label treatments and clinical trials, thus providing additional options if standard therapies are not suitable.
We can also help identify treatments that won’t work, thus reducing costs and the risk of any adverse reactions associated with their use.
What tests do you offer?
Next Generation Sequencing (NGS) based
Although we offer a full range of services in order to best fit the varied needs of customers, our core tests utilise NGS technology. This allows us to examine multiple genes simultaneously, thus gaining a better understanding of what may, or alternatively may not, be driving a patient’s cancer. This in turn gives us a better chance of finding something that can help fight it.
We offer a number of different NGS tests (click here for a general overview and here for specific details of exactly what is included in each) which have been developed and validated in-house (we are UKAS Accredited to ISO15189). These vary both in size (number of genes assessed) and complexity (types of genetic changes assessed). The latter depending upon whether they are based on DNA sequencing alone or a combination of both DNA & RNA sequencing. For unusual tumour types and/or those where target-able variants may exist in genes beyond those included in our in-house tests, we can also facilitate pre-analytical assessment and specimen referrals on to our carefully selected partner organisations.
In additional to NGS based tests we also offer a range of other molecular diagnostic assays providing diagnostic, prognostic and treatment stratification related information. These include:
- Ultra-rapid single gene (BRAF, KRAS, NRAS & EGFR) analyses, for use in time-critical solid tumour cases.
- Plasma based analysis of circulating tumour DNA (ctDNA) for EGFR mutations. Indicated when tissue based analyses may not be possible/desirable.
- B & T-Cell clonality analyses, for use in suspected lymphoproliferative diseases.
- Endopredict (from Myriad Genetics), for use in breast cancer patients to assess the relative risks/benefits of post surgical chemotherapy.
- Micro-satellite Instability (MSI) analysis, for use in assessing the likelihood of Lynch Syndrome and/or potential response to Check Point Inhibitor (CPI) therapy in certain tumours.
- MLH1 promotor methylation anaylsis, for use in conjunction with MSI, BRAF and/or immunohistochemistry to assess the likelihood of Lynch Syndrome.
As we are constantly developing and validating new tests to support and expand the existing repertoire, make sure you watch this space!
When might I refer a patient?
Our NGS based tests our best suited for patients with common solid tumours such lung, colorectal, skin, gastric and breast cancers. You can use our tests for patients who have just been diagnosed, to make sure they get the correct approved treatment from the word go. Alternatively, you can order for patients with more advanced disease, who have perhaps exhausted their standard care options. The latter allowing further ‘off-label’ or clinical trial opportunities to be explored.
Find out more about what our tests can tell you.
Why choose SCMD?
Launched in 2014, we were one of the first labs in the UK to start routine tumour profiling (i.e. for all cases by default) by NGS, and as a result have an extraordinary range of experience and expertise within our team. We have always stayed focused on clinically actionable targets making sure that our tests are as sensitive and robust as possible, meaning that we can successfully analyse very small low tumour content samples, with which many of our competitors may struggle.
Our laboratory is a partnership between:
HCA’s global Cancer Institute. Its research arm not only focuses on advancing therapies for patients, but is one of the world’s leading clinical research organisations conducting clinical trials. Sarah Cannon has been a clinical trial leader in the majority of cancer therapies over the last 10 years.